Artiva Biotherapeutics (ARTV) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Artiva Biotherapeutics (ARTV) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 126.7% versus a loss of 16.0%. Artiva Biotherapeutics is the larger company by market cap ($339.3 million vs $291.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | XFOR |
|---|---|---|
| Share price | $6.94 | $2.94 |
| Market cap | $339.30M | $291.00M |
| 1-day change | +2.06% | +5.20% |
| YTD return | +58.51% | -30.25% |
| 1-year return | +126.67% | -15.96% |
| 5-year return | — | -98.22% |
| P/E ratio (TTM) | — | 146.75 |
| EPS (TTM) | $-3.23 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.53 | $4.83 |
| 52-week low | $2.71 | $2.70 |
| Distance from 52-week high | -52.24% | -39.23% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +415.85% | +295.23% |
| Average volume | 403.56K | 849.58K |
| Shares outstanding | 48.89M | 99.15M |
| Employees | 115 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARTV has outperformed XFOR by 142.6 percentage points over the past year.
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 115 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
ARTV vs XFOR FAQ
Which is bigger, Artiva Biotherapeutics or X4 Pharmaceuticals?
Artiva Biotherapeutics (ARTV) is larger, with a market capitalization of $339.30M compared with $291.00M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, ARTV or XFOR?
ARTV returned +126.67% over the past 12 months, compared with -15.96% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Are Artiva Biotherapeutics and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.